Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0102069Aexternal-prioritypatent/SE0102069D0/en
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Publication of UY27345A1publicationCriticalpatent/UY27345A1/en
Una formulación farmacéutica oral que comprende musgo de Irlanda-iota, uno o más polímeros gelficantes neutros y un ingrediente básico farmacéuticamente activo, formulación que inhibe la liberación del ingrediente básico farmacéuticamente activo de la formulación a pH ácido, un proceso para la fabricación de dicha formulación y el uso de la formulación en medicina.An oral pharmaceutical formulation comprising Irish-iota moss, one or more neutral gelating polymers and a pharmaceutically active basic ingredient, formulation that inhibits the release of the pharmaceutically active basic ingredient from the formulation at acidic pH, a process for manufacturing said formulation and the use of the formulation in medicine.
Oral dosage form comprising an erodible core that contains an active principle of a weak basic character, an erodible coating around said core with one or more openings that pass through the coating and connect the core with the means of use; preparation procedure; and use (divisional of 260-03).
A PHARMACEUTICAL FORMULATION WITH A MATRIX THAT FORM A HYDROPHILIC GEL, FORMULATION THAT INCLUDES ONE OR MORE ACTIVE SUBSTANCES, AND METHOD TO PREPARE SUCH FORMULATION THAT HAS A SUBSTANTIELY INDEPENDENT PROLONGED RELEASE OF THE IONIC FORCE